Authors : Abhinav Choubey

Volume/Issue : Volume 9 - 2024, Issue 10 - October

Google Scholar : https://tinyurl.com/bddrctd9

Scribd : https://tinyurl.com/3ktd7t5b

DOI : https://doi.org/10.38124/ijisrt/IJISRT24OCT145

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Asthma remains a significant public health issue in India, with a growing number of patients experiencing severe and uncontrolled forms of the disease. Targeted biologic therapies, including omalizumab, mepolizumab, benralizumab, reslizumab, and dupilumab, have emerged as advanced treatment options for patients with severe asthma, especially those with allergic or eosinophilic phenotypes. These therapies work by targeting specific immunological pathways involved in asthma pathogenesis, offering better symptom control and reducing exacerbation rates. However, the high cost of biologics, limited access, and inconsistent insurance coverage pose significant barriers to their widespread use in India. Despite these challenges, real-world data from Indian studies demonstrate promising clinical outcomes with biologic therapies in patients with difficult-to-treat asthma. This review examines the current landscape of biologic use in India, challenges related to cost and accessibility, and future prospects for integrating these treatments into routine asthma care, particularly through cost- reduction strategies and expanded healthcare coverage.

References :

1. World Health Organization. Global Asthma Report 2018.
2. Global Initiative for Asthma (GINA) Report, 2023.
3. Bousquet J, et al. “Asthma Control: The Role of Biologic Therapies.” The Lancet, 2020.
4. Busse WW. “Biologics for Asthma: A 2020 Review.” Journal of Allergy and Clinical Immunology, 2020.
5. Holgate ST, et al. “IgE and Omalizumab in Severe Asthma.” New England Journal of Medicine, 2019.
6. Pavord ID, et al. “Eosinophilic Asthma and IL-5 Targeting.” The Lancet, 2021.
7. Castro M, et al. “Dupilumab in Type 2 Inflammation.” Journal of Asthma, 2021.
8. Vijayan VK. “Biologics in the Treatment of Asthma: Indian Experience.” Lung India, 2019.
9. Koul PA. “Use of Omalizumab in India: Barriers and Solutions.” Journal of Respiratory Medicine, 2020.
10. Mukherjee M, et al. “Anti-IL-5 Therapy for Asthma in India.” Indian Journal of Chest Diseases, 2021.
11. Ghosh B, et al. “Challenges in Access to Biologics for Asthma in India.” Journal of Clinical Pulmonology, 2022.
12. Shah A. “Dupilumab in Severe Asthma: Indian Experience.” Chest India, 2023.
13. Gupta A. “Real-world Use of Biologics for Asthma in India.” Respiratory Research, 2021.
14. “High Cost of Biologics in India: Implications for Asthma Treatment.” Journal of Clinical Pulmonology, 2021.
15. Tripathi R, et al. “Addressing the Gaps in Biologic Use in Indian Asthma Care.” Journal of Allergy and Asthma, 2022.
16. Verma A, et al. “Diagnostic Challenges in Severe Asthma Management in India.” Lung India, 2020.
17. Nair A. “Educational Gaps in Biologic Therapies for Asthma.” Indian Journal of Allergy, 2021.
18. World Bank. “Expanding Access to Healthcare in India.” Report 2021.
19. Singh T, et al. “Home-Based Administration of Biologics: Feasibility and Challenges in India.” Journal of Asthma Care, 2023.
20. Raman S, Kumar M. “Telemedicine Integration in Biologic Therapy for Asthma: A Future Outlook.” Journal of Clinical Asthma, 2022;14(1):45-50.